MRZ

DRUG2 trials

Sponsors

Celgene

Conditions

GlioblastomaMalignant Glioma

Phase 1

Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab

CompletedNCT02330562

CelgeneGlioblastoma, Malignant Glioma

Start: 2015-04-15End: 2021-06-02Updated: 2022-06-08

Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer

CompletedNCT02903069

CelgeneGlioblastoma, Malignant Glioma

Start: 2016-08-17End: 2021-01-25Updated: 2021-04-19

Related Papers

Proteasome inhibition as a therapeutic approach in atypical teratoid/rhabdoid tumors

Neuro-Oncology Advances2020-01-0117 citations

Abstract 4733: Human functional brain imaging data support preclinical and clinical evidence that marizomib crosses the blood-brain barrier (BBB) to inhibit proteasome activity in the brain

Cancer Research2019-07-012 citations

Abstract 4733: Human functional brain imaging data support preclinical and clinical evidence that marizomib crosses the blood-brain barrier (BBB) to inhibit proteasome activity in the brain

Experimental and Molecular Therapeutics2019-07-01

Full enrollment results from an extended phase I, multicenter, open label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed glioblastoma (GBM).

Journal of Clinical Oncology2019-05-2010 citations

ACTR-40. A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) WITH TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, ndGBM): FULL ENROLLMENT RESULTS

Neuro-Oncology2018-11-011 citations

ATRT-18. VALIDATION OF PROTEASOME INHIBITION AS A THERAPEUTIC TARGET IN ATYPICAL TERATOID/RHABDOID TUMORS

Neuro-Oncology2018-06-01

A phase 1, multicenter, open-label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed WHO grade IV malignant glioma (glioblastoma, ndGBM): Dose-escalation results.

Journal of Clinical Oncology2018-05-206 citations

ACTR-45. A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) WITH TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, ndGBM)

Neuro-Oncology2017-11-01

Abstract 3069: Investigation of pharmacodynamic and predictive biomarkers to define response to proteasome inhibitor marizomib in glioma

Cancer Research2016-07-151 citations

Phase 1, multicenter, open-label, dose-escalation, study of marizomib (MRZ) and bevacizumab (BEV) in WHO grade IV malignant glioma (G4 MG).

Journal of Clinical Oncology2016-05-203 citations